尊龙凯时网址 copyright © pharmcube all right reserved 2024尊龙凯时网址 copyright © pharmcube all right reserved 2024pharmcube.com 尊龙凯时网址 copyright © pharmcube all right reserved 20242024年5月全球新药转化医学 重要研发/注册进展 前沿专利2024-05医药魔方全球新药研究团队 尊龙凯时网址 copyright © pharmcube all right reserved 2024尊龙凯时网址 copyright © pharmcube all right reserved 20243尊龙凯时网址 copyright © pharmcube all right reserved 2024尊龙凯时网址 copyright © pharmcube all right reserved 20243nextpharma全球新药数据库：聚焦临床开发数据加速新药情报获取药物疾病靶点公司按技术、区域、作用机制的产品筛选管线产品检索靶点图谱靶点疾病开发图景公司产品线搜索新闻、权益交易监控领域靶点热度分析基于方案、领域、靶点、治疗线的临床结果筛选临床试验结果药品综述靶点热度公司概览页成熟、积极、消极靶点药品/靶点联用检索企业类型筛选•本报告中涉及到的主要数据均来自于nextpharma全球新药数据库。如需了解数字背后的详细数据，请扫描左侧二维码申请查看&申请试用。扫码申请数据库试用 尊龙凯时网址 copyright © pharmcube all right reserved 2024尊龙凯时网址 copyright © pharmcube all right reserved 20244尊龙凯时网址 copyright © pharmcube all right reserved 2024尊龙凯时网址 copyright © pharmcube all right reserved 20244免责声明•本报告由医药魔方制作 , 仅供购买用户使用。未经允许，严禁将本报告大规模传阅。•医药魔方不对本报告内的数据做超出客户服务协议之外的承诺。本报告不构成任何立项、投资、交易建议。阅读者应审慎使用本报告信息。医药魔方不会因为接收人收到本报告而视其为客户。•对本报告有任何疑问和建议或者是数据上的需求，欢迎扫码添加魔方君企业微信联系。http://www.pharmcube.com联系尊龙凯时网址上海市张江高科技园区亮秀路112号y1座611室苏州市工业园区星湖街218号b6楼2楼南京市鼓楼区中山北路2号紫峰大厦主楼1910室email： hi@pharmcube.comtel：010-64736966 / 021-66292268北京市朝阳区宝能中心a座1308室 尊龙凯时网址 copyright © pharmcube all right reserved 2024尊龙凯时网址 copyright © pharmcube all right reserved 20245尊龙凯时网址 copyright © pharmcube all right reserved 2024尊龙凯时网址 copyright © pharmcube all right reserved 20245•官方公开披露的信息数据来源数据分析范围•2024年05月，全球转化医学、最新药物注册/研发进展、前沿专利• 包含传统定义药品，如化药和生物制品等，及其相关公司技术等•不包含战略技术合作类、cmo类、cro类 尊龙凯时网址 copyright © pharmcube all right reserved 2024尊龙凯时网址 copyright © pharmcube all right reserved 20246尊龙凯时网址 copyright © pharmcube all right reserved 2024尊龙凯时网址 copyright © pharmcube all right reserved 2024612024年05月转化医学2024年05月研发进展•早期研发项目进展c o n t e n t •2024年05月全球批准新药•2024年05月fda授予突破性疗法资格22024年05月注册进展42024年05月研发/注册进展附录52024年05月前沿专利3•转化医学里程碑关注 尊龙凯时网址 copyright © pharmcube all right reserved 202401.转化医学•转化医学里程碑关注 尊龙凯时网址 copyright © pharmcube all right reserved 2024尊龙凯时网址 copyright © pharmcube all right reserved 202482024年5月转化医学里程碑关注 (1/2)pmid期刊标题药品(当前最高阶段)靶点疾病主题类型38744281cellosr2 functions as a biomechanical checkpoint to aggravate cd8 tcell exhaustion in tumor.osr2肿瘤靶点/标志物38600376naturefoxo1 enhances car t cell stemness, metabolic fitness and efficacy.foxo1癌症靶点/标志物38600391naturefoxo1 is a master regulator of memory programming in car t cells.foxo1癌症靶点/标志物38811738naturea gram-negative-selective antibiotic that spares the gut microbiome.lolamicin(临床前)not available细菌感染药物发现38781365sciencereversible male contraception by targeted inhibition of serine/threonine kinase 33.cdd-2807(临床前)stk33男性避孕药物发现38778101natureselective haematologicalcancer eradication with preserved haematopoiesis.shielded hscs from cd45-targeting immunotherapy(临床前)cd45血癌; 急性髓系白血病药物发现38720069naturediscovery of potent small-molecule inhibitors of lipoprotein(a) formation.muvalaplin(ii期临床)apo(a)脂蛋白(a)增高药物发现38750368natureglp-1-directed nmda receptor antagonism for obesity treatment.glp-1-mk-801(临床前)glp-1; nmda receptor肥胖药物发现38815015sciencepharmacological modulation of septinsrestores calcium homeostasis and is neuroprotective in models of alzheimer's disease.res19-t(ii期临床)not available阿尔茨海默病非临床38753769sciencevaccine priming of rare hiv broadly neutralizing antibody precursors in nonhuman primates.n332-gt5 gp120(临床前)gp120hiv-1感染非临床38810646cellstructure-based discovery of cftr potentiators and inhibitors.cftr结构数据来源：医药魔方nextpharma®数据库 尊龙凯时网址 copyright © pharmcube all right reserved 2024尊龙凯时网址 copyright © pharmcube all right reserved 202492024年5月转化医学里程碑关注 (2/2)pmid期刊标题药品(当前最高阶段)靶点疾病主题类型38753770sciencemrna-lnp hiv-1 trimer boosters elicit precursors to broad neutralizing antibodies.hiv-1感染技术38753766sciencean aav capsid reprogrammed to bind human transferrin receptor mediates brain-wide gene delivery.tfr1技术38280389lancetaav1-hotof gene therapy for autosomal recessive deafness 9: a single-arm trial.rrg-003(i期临床)otof听力损失初步临床38740803cell discovefficacy and safety of novel multifunctional m10 car-t cells in hiv-1-infected patients: a phase i, multicenter, single-arm, open-label studym10 car-t (上海市公共卫生临床中心)(i期临床)cxcr5hiv-1感染初步临床am j respir crit care medenv-101, a novel hedgehog inhibitor, increases lung function, and reduces lung fibrosis in patients with idiopathic pulmonary fibrosis: results from a randomized, double-blind, placebo-controlled phase 2 trialtaladegib(ii期临床)smoothened特发性肺纤维化初步临床eha 2024completed dose escalation from the first-in-human, phase 1/2study of cd123 nk cell engager, sar443579, in relapsed orrefractory acute myeloid leukemia or high risk-myelodysplasiasar443579(ii期临床)nkp46; cd16a; cd123急性髓系白血病初步临床2024 asco annual meetingphase 1 study of nb003, a broad-spectrum kit/pdgfrα inhibitor, in patients with advanced gastrointestinal stromal tumors (gist).azd3229(i期临床)scf/c-kit; pdgfrα胃肠道间质瘤初步临床positive statistically significant phase 2 clinical trial results of biodexa'snewly-licensed erapain familial adenomatous polyposis (fap)erapa (西罗莫司)(ii期临床)mtor; mtorc1; fkbp12家族性腺瘤性息肉病初步临床the potential of tezspire to play a role in the future treatment of chronic obstructive pulmonary diseasetezepelumab(批准上市)tslp